| OPPOSITION | - Alex Kiselyov, Svetlana Bunimovich-Mendrazitsky , Vladimir Startsev, "Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment", Int. J. Cancer, (20150000), vol. 138, pages 2562 - 2569 | - |
| OPPOSITION | - Alex Kiselyov, Svetlana Bunimovich-Mendrazitsky , Vladimir Startsev, "Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment", Int. J. Cancer, (20150000), vol. 138, pages 2562 - 2569, XP055763576 | - |
| OPPOSITION | - Anonymous, "Comprehensive molecular characterization of urothelial bladder carcinoma -Cancer Genome Atlas Research Network", Nature, (20140000), vol. 507, no. 7492, pages 315 - 322, XP055763554 | - |
| OPPOSITION | - Anonymous, "History of changes or study: NCT02543645. A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", ClinicalTrials.gov archive, (20150904), pages 1 - 4, XP055763778 | - |
| OPPOSITION | - Antonio D. Bardoli, Mehran Afshar , Richard Viney , Mike Foster , Emilio Porfiri , Anjali Zarkar , Robert Stevenson, Nicholas D James , Richard T Bryan , Prashant Patel, "The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target", Future Oncology, (20160000), vol. 12, no. 5, pages 595 - 600 | - |
| OPPOSITION | - Antonio D. Bardoli, Mehran Afshar , Richard Viney , Mike Foster , Emilio Porfiri , Anjali Zarkar , Robert Stevenson, Nicholas D James , Richard T Bryan , Prashant Patel, "The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target", Future Oncology, (20160000), vol. 12, no. 5, pages 595 - 600, XP055763594 | - |
| OPPOSITION | - BELLMUNT J; POWLES T & VOGELZANG N J, "A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now", Cancer Treatment Reviews, (20170000), vol. 54, pages 58 - 67 | - |
| OPPOSITION | - Bidnur S; Savdie R; Black P C, "Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer", Bladder Cancer, (20160000), vol. 2, no. 1, pages 15 - 25 | - |
| OPPOSITION | - Cheng Liang, Darrell D Davison , Julia Adams , Antonio Lopez-Beltran , Lisha Wang , Rodolfo Montironi , Shaobo Zhang, "Biomarkers in bladder cancer: Translational and clinical implications", Crit Rev Oncol Hematol, (20140100), vol. 89, no. 1, pages 73 - 111, XP055763784 | - |
| OPPOSITION | - Choi et al., Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul;ll(7):400- 10. doi: 10.1038/nrurol.2014.129. | - |
| OPPOSITION | - DavidH Aggen; CharlesG Drake, "Biomarkers for immunotherapy in bladder cancer: a moving target", Journal for ImmunoTherapy of Cancer, (20170000), vol. 5, no. 94, pages 1 - 13 | - |
| OPPOSITION | - David J McConkey , Woonyoung Choi, Colin P N Dinney, "Genetics subtypes of invasive bladder cancer", Curr. Opin. Urol., (20150000), vol. 25, pages 449 - 458 | - |
| OPPOSITION | - David J McConkey , Woonyoung Choi, Colin P N Dinney, "Genetics subtypes of invasive bladder cancer", Curr. Opin. Urol., (20150000), vol. 25, pages 449 - 458, XP055763584 | - |
| OPPOSITION | - Emmanuel Seront, Jean-Pascal Machiels, "Molecular biology and targeted therapies for urothelial carcinoma", Cancer Treatment Reviews, (20150000), vol. 41, pages 341 - 353, XP05576358 | - |
| OPPOSITION | - Galsky M. D., M. Retz A.O. Siefker-Radtke A. Baron A. Necchi J. Bedke E.R. Plimack D. Vaena M.-O. Grimm S. Bracarda J. Arranz Arija S.K. Pal C. Ohyama A. Saci A. Lambert S. Krishnan A. Azrilevich P. Sharma, "Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study", Annals of Oncology 27, (20160000), pages vi552 - vi587, XP055763545 | - |
| OPPOSITION | - Jean-Michel Lavoie; Peter C Black; Bernhard J Eigl, "Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review", J Urol, (20190700), vol. 202, no. 1, pages 49 - 56, XP055763537 | - |
| OPPOSITION | - LAVOIE et al., "Predictive biomarkers for checkpoint blockade in urothelial cancer: a systematic review", J. Urology, (20190000), vol. 202, pages 49 - 56 | - |
| OPPOSITION | - LAVOIE et al., "Predictive biomarkers for checkpoint blockade in urothelial cancer: a systematic review", J. Urology, (20190000), vol. 202, pages 49 - 56, XP055763537 | - |
| OPPOSITION | - Lenis Andrew T., Karim Chamie, "Bladder cancer in 2014: From the genomic frontier to immunotherapeutics", Nat Rev Urol, (20150200), vol. 12, no. 2, pages 74 - 76, XP055763781 | - |
| OPPOSITION | - MCCONKEY et al., "Genetic subtypes of invasive bladder cancer", Curr Opin Urol, (20150900), vol. 25, no. 5, pages 449 - 458, XP055763791 | - |
| OPPOSITION | - Petrylak Daniel Peter, Thomas Powles , Joaquim Bellmunt , Fadi S. Braiteh , Yohann Loriot , Cristina Cruz Zambranohoward A. Burris , Joseph W. Kim , Siew-Leng Melinda Teng , Jean-Marie Bruey , Priti Hegde , Oyewale O. Abidoye , Nicholas J. Vogelzang, "A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).", Journal of Clinical Oncology, (20150000), vol. 33, no. 15, page 1 | - |
| OPPOSITION | - Petrylak Daniel Peter, Thomas Powles , Joaquim Bellmunt , Fadi S. Braiteh , Yohann Loriot , Cristina Cruz Zambranohoward A. Burris , Joseph W. Kim , Siew-Leng Melinda Teng , Jean-Marie Bruey , Priti Hegde , Oyewale O. Abidoye , Nicholas J. Vogelzang, "A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).", Journal of Clinical Oncology, (20150000), vol. 33, no. 15, page 1, XP055763488 | - |
| OPPOSITION | - PLIMACK et al., "Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.", Journal of Clinical Oncology, (20150000), vol. 33, no. 15, page 1 | - |
| OPPOSITION | - PLIMACK et al., "Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.", Journal of Clinical Oncology, (20150000), vol. 33, no. 15, page 1, XP055763501 | - |
| OPPOSITION | - Roche Press Release - 27 September 2015 | - |
| OPPOSITION | - ROSENBERG et al., "Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210", European Journal of Cancer, (20150900), vol. 51, no. 3, page S720, XP055763515 | - |
| OPPOSITION | - Rosenberg et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. | - |
| OPPOSITION | - Rosenberg, J; Petrylak, D; Abidoye, O; Van der Heijden, MS; Hofman-Censits, J; Necchi, A; O'Donnell, PH; Balmanoukian, A; Loriot, Y; Retz, M, "Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)", European Journal of Cancer, (20150000), vol. 51, page S720 | - |
| OPPOSITION | - Rosenberg, J; Petrylak, D; Abidoye, O; Van der Heijden, MS; Hofman-Censits, J; Necchi, A; O'Donnell, PH; Balmanoukian, A; Loriot, Y; Retz, M, "Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)", European Journal of Cancer, (20150000), vol. 51, page S720, XP055763515 | - |
| OPPOSITION | - Sanjeev Mariathasan; Turley Shannon J; Nickles Dorothee; Castiglioni Alessandra; Yuen Kobe; Wang Yulei; Kadel Iii Edward E; Koeppen Hartmut; Astarita Jillian L; Cubas Rafael; Jhunjhunwala Suchit; Banchereau Romain; Yang Yagai; Guan Yinghui; Chalouni Cecile; Ziai James; Şenbabaoğlu Yasin; Santoro Stephen; Sheinson Daniel; Hung Jeffrey; Giltnane Jennifer M; Pierce Andrew A; Mesh Kathryn; Lianoglou Steve; Riegler Johannes; Carano Richard A D; Eriksson Pontus; Höglund Mattias; Somarriba Loan; Halligan Daniel L; Van Der Heijden Michiel S; Loriot Yohann; Rosenberg Jonathan E; Fong Lawrence; Mellman Ira; Chen Daniel S; Green Marjorie; Derleth Christina; Fine Gregg D; Hegde Priti S; Bourgon Richard; Powles Thomas, "TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells", Nature, (20180000), vol. 554, no. 7693, pages 544 - 548 | - |
| OPPOSITION | - Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-Leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang, "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer", Nature, (20140000), vol. 515, pages 558 - 562 | - |
| OPPOSITION | - Zhu Shaoming, Weimin Yu , Xiao Yang , Cheng Wu , Fan Cheng, "Traditional classification and novel subtyping systems for bladder cancer", Frontiers in Oncology, (20200000), vol. 10, pages 1 - 13 | - |
| OPPOSITION | - Zhu Shaoming, Weimin Yu , Xiao Yang , Cheng Wu , Fan Cheng, "Traditional classification and novel subtyping systems for bladder cancer", Frontiers in Oncology, (20200000), vol. 10, pages 1 - 13, XP055763510 | - |
| OPPOSITION | - BELLMUNT J; POWLES T & VOGELZANG N J, "A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now", Cancer Treatment Reviews, (20170000), vol. 54, pages 58 - 67, XP002776036 | |
| OPPOSITION | - Kim C Ohaegbulam; Amer Assal; Eszter Lazar-Molnar; Yu Yao; Xingxing Zang, "Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway", Trends Mol. Med., (20150000), vol. 21, no. 1, pages 24 - 33, XP055249717 | |
| OPPOSITION | - ROSENBERG et al., "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum- based chemotherapy: a single-arm, multicentre, phase 2 trial.", Lancet, (20160507), vol. 387, no. 10031, doi:10.1016/S0140-6736(16)00561-4, pages 1909 - 20, XP029530539 | |
| OPPOSITION | - Rosenberg Jonathan E; Hoffman-Censits Jean; Powles Tom; van der Heijden Michiel S; Balar Arjun V; Necchi Andrea; Dawson Nancy; O'Donnell Peter H; Balmanoukian Ani; Loriot Yohann; Srinivas Sandy; Retz Margitta M; Grivas Petros; Joseph Richard W; Galsky Matthew D; Fleming Mark T; Petrylak Daniel P; Perez-Gracia Jose Luis; Burris Howard A; Castellano Daniel; Canil Christina; Bellmunt Joaquim; Bajorin Dean; Nickles Dorothee; Bourgon Richard; Frampton Garrett M; Cui Na; Mariathasan Sanjeev; Abidoye Oyewale; Fine Gregg D; Dreicer Robert, "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial", Lancet, (20160000), vol. 387, pages 1909 - 920, XP029530539 | |
| OPPOSITION | - BALAR et al., "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial", Lancet, (20170107), vol. 389, no. 10064, doi:10.1016/S0140-6736(16)32455-2, pages 67 - 76, XP029877685 | |
| OPPOSITION | - POWLES et al., "Atezolizumab versus chemotherapy in patients with platinum- treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial", Lancet, (20180224), vol. 391, no. 10122, doi:10.1016/S0140-6736(17)33297-X, pages 748 - 757, XP055645308 | |
| OPPOSITION | - SHARMA et al., "Nivolumab in metastatic urothelial carcinoma after bplatinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial", Lancet Onco l, (20170300), vol. 18, no. 3, doi:10.1016/S1470-2045(17)30065-7, pages 312 - 322, XP055682224 | |
| OPPOSITION | - POWLES et al., "MPDL3280A (anti-PD-Ll) treatment leads to clinical activity in metastatic bladder cancer", Nature, (20141127), vol. 515, no. 7528, doi:10.1038/nature13904, pages 558 - 62, XP055207741 | |
| OPPOSITION | - Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-Leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang, "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer", Nature, (20140000), vol. 515, pages 558 - 562, XP055207652 | |
| OPPOSITION | - Sanjeev Mariathasan; Turley Shannon J; Nickles Dorothee; Castiglioni Alessandra; Yuen Kobe; Wang Yulei; Kadel Iii Edward E; Koeppen Hartmut; Astarita Jillian L; Cubas Rafael; Jhunjhunwala Suchit; Banchereau Romain; Yang Yagai; Guan Yinghui; Chalouni Cecile; Ziai James; Şenbabaoğlu Yasin; Santoro Stephen; Sheinson Daniel; Hung Jeffrey; Giltnane Jennifer M; Pierce Andrew A; Mesh Kathryn; Lianoglou Steve; Riegler Johannes; Carano Richard A D; Eriksson Pontus; Höglund Mattias; Somarriba Loan; Halligan Daniel L; Van Der Heijden Michiel S; Loriot Yohann; Rosenberg Jonathan E; Fong Lawrence; Mellman Ira; Chen Daniel S; Green Marjorie; Derleth Christina; Fine Gregg D; Hegde Priti S; Bourgon Richard; Powles Thomas, "TGF[3 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells", Nature, (20180222), vol. 554, no. 7693, pages 544 - 548, XP055488784 | |
| OPPOSITION | - Sanjeev Mariathasan; Turley Shannon J; Nickles Dorothee; Castiglioni Alessandra; Yuen Kobe; Wang Yulei; Kadel Iii Edward E; Koeppen Hartmut; Astarita Jillian L; Cubas Rafael; Jhunjhunwala Suchit; Banchereau Romain; Yang Yagai; Guan Yinghui; Chalouni Cecile; Ziai James; Şenbabaoğlu Yasin; Santoro Stephen; Sheinson Daniel; Hung Jeffrey; Giltnane Jennifer M; Pierce Andrew A; Mesh Kathryn; Lianoglou Steve; Riegler Johannes; Carano Richard A D; Eriksson Pontus; Höglund Mattias; Somarriba Loan; Halligan Daniel L; Van Der Heijden Michiel S; Loriot Yohann; Rosenberg Jonathan E; Fong Lawrence; Mellman Ira; Chen Daniel S; Green Marjorie; Derleth Christina; Fine Gregg D; Hegde Priti S; Bourgon Richard; Powles Thomas, "TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells", Nature, (20180000), vol. 554, no. 7693, pages 544 - 548, XP055488784 | |
| OPPOSITION | - DONG et al., "Tumor-associated B7-H1 promotes T- cell apoptosis: a potential mechanism of immune evasion", Nat Med, (20020000), vol. 8, no. 8, doi:10.1038/nm730, pages 793 - 800, XP002397368 | |
| OPPOSITION | - CHOI et al., "Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer", Nat Rev Urol., (20140700), vol. 11, no. 7, doi:10.1038/nrurol.2014.129, pages 400 - 10, XP055269413 | |
| OPPOSITION | - Thomas Powles; Dorothee Nickles; Eliezer Van Allen; Colombe Chappey; Wei Zou; Marcin Kowanetz; Edward Kadel; Mitchell Denker; Zachary Boyd; Nicholas Vogelzang; Joseph Kim; Joaquim Bellmunt; Yohann Loriot; CharlesG Drake; Carol O'Hear; Marcella Fasso; Priti Hegde; Sanjeev Mariathasan, "Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)", Journal for ImmunoTherapy of Cancer, (20150000), vol. 3, no. 2, pages 1 - 2, XP021235673 | |
| OPPOSITION | - DavidH Aggen; CharlesG Drake, "Biomarkers for immunotherapy in bladder cancer: a moving target", Journal for ImmunoTherapy of Cancer, (20170000), vol. 5, no. 94, pages 1 - 13, XP021250714 | |
| OPPOSITION | - BALLMAN et al., "Biomarker: Predictive or Prognostic?", J Clin Oncol., (20151120), vol. 33, no. 33, doi:10.1200/JCO.2015.63.3651, pages 3968 - 71, XP055704631 | |
| OPPOSITION | - Bidnur S; Savdie R; Black P C, "Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer", Bladder Cancer, (20160000), vol. 2, no. 1, pages 15 - 25, XP055439493 | |
